Pfizer FY2025 EPS Forecast Lowered by Cantor Fitzgerald

Pfizer Inc. (NYSE:PFE) – Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Pfizer in a research note issued on Thursday, October 9th. Cantor Fitzgerald analyst C. Gould now expects that the biopharmaceutical company will post earnings of $3.05 per share for the year, down from their prior estimate of $3.15. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Cantor Fitzgerald also issued estimates for Pfizer’s FY2026 earnings at $3.09 EPS.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS.

A number of other analysts have also weighed in on the stock. Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Bank of America lifted their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. UBS Group restated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Morgan Stanley lowered their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average price target of $28.35.

Pfizer Trading Down 0.3%

Shares of Pfizer stock opened at $24.72 on Monday. The company’s 50-day moving average price is $24.88 and its 200-day moving average price is $24.12. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer has a 12-month low of $20.92 and a 12-month high of $29.82. The company has a market cap of $140.52 billion, a price-to-earnings ratio of 13.15, a PEG ratio of 0.82 and a beta of 0.55.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in PFE. Capital Advisory Group Advisory Services LLC raised its stake in Pfizer by 2.9% in the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after buying an additional 388 shares during the last quarter. Citizens National Bank Trust Department grew its stake in shares of Pfizer by 0.9% during the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after acquiring an additional 395 shares during the last quarter. Peak Asset Management LLC increased its holdings in shares of Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after acquiring an additional 402 shares in the last quarter. Able Wealth Management LLC raised its position in shares of Pfizer by 2.0% in the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 413 shares during the last quarter. Finally, Boltwood Capital Management boosted its stake in Pfizer by 0.7% in the 3rd quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock worth $1,485,000 after purchasing an additional 420 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s dividend payout ratio is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.